Physician profile
Robert Michael Baskin
NPI 1194011437
$3,228.41
in general payments reported to CMS, 2019-2025
13 companies · $710 in 2025
The $710 reported for 2025 was more than what a typical Otolaryngology provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $802 · 2021: $106 · 2022: $1,494 · 2023: $72.91 · 2024: $43.14 · 2025: $710.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $826.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $1,461.19 | 2022-2025 | Scopis Ent |
| Medtronic USA, INC. | $733.81 | 2020 | |
| Optinose US, INC. | $163.86 | 2021-2024 | |
| Aerin Medical INC. | $161.61 | 2025 | |
| Intersect Ent, INC. | $151.66 | 2020-2022 | |
| Integra Lifesciences Corporation | $150.00 | 2025 | Relieva Spinplus Nav, Inspira Air, Acclarent Aera |
| Genzyme Corporation | $122.96 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $118.16 | 2021-2025 | Dupixent |
| Inspire Medical Systems, INC. | $71.97 | 2025 | Inspire |
| Sumitomo Pharma America, INC. | $37.51 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $25.15 | 2023 | |
| Smith+Nephew, INC. | $24.00 | 2025 | Tula |
| Phathom Pharmaceuticals, INC. | $6.53 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Baskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.